Back to Stock Dashboard
Sector:
Healthcare
Add to portfolio
HYFT
ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. (HYFT) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B-); its weakest is Revisions (C-).
Quantitative Factor Evaluation • Updated
Overall Rating
2.6
/ 5.0
C+
Value
C+
Factor Score
2.7
/ 5.0
Growth
B-
Factor Score
3.0
/ 5.0
Profitability
B-
Factor Score
2.9
/ 5.0
Momentum
C
Factor Score
2.4
/ 5.0
Revisions
C-
Factor Score
1.9
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
0.0
EV / EBITDA
-4.7
Rev Growth YoY
49.8%
Gross Margin
58.8%
Price Return 3M
9.7%
Price Return 12M
-17.1%
Catalyst Signal
0.00
Market Cap
N/A
TTM Revenue
N/A
Price / Sales
4.1
ROE
-85.4%
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-08-05 | C+ (2.7) | B- (3.0) | B- (2.9) | C (2.4) | C- (1.9) | C+ (2.6) |
| 2026-08-04 | C+ (2.7) | B- (3.0) | B- (2.9) | C (2.4) | C- (1.9) | C+ (2.6) |
| 2026-08-03 | C+ (2.7) | C+ (2.6) | B- (3.0) | C (2.4) | C- (2.0) | C+ (2.5) |
| 2026-08-02 | C+ (2.7) | C+ (2.6) | B- (3.0) | C (2.4) | C- (1.9) | C+ (2.5) |